Results 171 to 180 of about 10,268 (212)
Association between <i>CYP2C19</i> polymorphism and proton pump inhibitors adverse drug reactions: a narrative review. [PDF]
Front PharmacolIbrahim A, Yusuff K, Awaisu A, Elewa H.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Lansoprazole-Induced Thrombocytopenia
Annals of Pharmacotherapy, 2002OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole. CASE SUMMARY: An 85-year-old white man presented with an upper gastrointestinal hemorrhage from a gastric ulcer. His platelet count was normal on admission.
Jonathan A Zlabek +1 more
openaire +2 more sources
Lansoprazole: A Comprehensive Review
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1997Lansoprazole is the second member of the substituted benzimidazole class of antisecretory agents approved for use in the United States. These drugs decrease parietal cell acid secretion by inhibiting H+,K+‐adenosine triphosphatase, the final step in the secretion of acid.
Anthony E. Zimmermann, Brian G. Katona
openaire +3 more sources
Pediatric Drugs, 2003
As reported in the accompanying article, lansoprazole has been successfully used in the treatment of children with GERD. It was well tolerated, and was effective in providing symptomatic relief in several pediatric studies. Constipation, vomiting, dizziness, diarrhea, headache or insomnia may occur in 3 years’ duration) use of proton pump inhibitors ...
openaire +5 more sources
As reported in the accompanying article, lansoprazole has been successfully used in the treatment of children with GERD. It was well tolerated, and was effective in providing symptomatic relief in several pediatric studies. Constipation, vomiting, dizziness, diarrhea, headache or insomnia may occur in 3 years’ duration) use of proton pump inhibitors ...
openaire +5 more sources
Clinical Pharmacokinetics of Lansoprazole
Clinical Pharmacokinetics, 1995Lansoprazole, a benzimidazole derivative with antisecretory and antiulcer activities, inhibits the acid pump activity at the final stage of the enzyme process and therefore reduces the acid secretion of parietal cells. Lansoprazole is converted to active metabolites in the acid environment of these cells.
Flouvat B, Landes Bd, Petite Jp
openaire +3 more sources
Drugs, 2004
An intravenous formulation of lansoprazole, a proton pump inhibitor, is approved for use in patients with erosive oesophagitis who are temporarily unable to take oral lansoprazole. In healthy volunteers, oral and intravenous lansoprazole 30 mg/day were equivalent in suppressing basal and pentagastrin-stimulated maximum gastric acid output.
Toni M Dando, Greg L. Plosker
openaire +3 more sources
An intravenous formulation of lansoprazole, a proton pump inhibitor, is approved for use in patients with erosive oesophagitis who are temporarily unable to take oral lansoprazole. In healthy volunteers, oral and intravenous lansoprazole 30 mg/day were equivalent in suppressing basal and pentagastrin-stimulated maximum gastric acid output.
Toni M Dando, Greg L. Plosker
openaire +3 more sources